Harley-Davidson (United States)

Interrogating molecular biomarkers in bodily fluids has emerged as a clinically useful strategy for the early diagnosis of many cancer types. Interstitial skin fluid is currently being explored as a possible alternative to blood, containing the same types of biomarkers but lacking cells and debris that hold little or no clinical value. The discovery and validation of molecular biomarkers with diagnostic or prognostic value and the development of clinical tests based on their detection require minimally invasive technologies capable of sampling this fluid in a pain-free manner. Biomarkers must also be easily recoverable for follow-on analysis. Herein, we combine standard genomic approaches with innovative bioengineering technologies to demonstrate that short noncoding miRNAs are significantly deregulated in extracellular skin fluid surrounding malignant skin lesions, providing a yet largely unexplored window of opportunity for early diagnosis of skin cancers. Hydrogel-based microneedle patches offering clinically useful sampling capacity were developed that enable the rapid capture and recovery of endogenous miRNAs from human skin through deformation of the epidermal-dermal junction. Using mouse models of cutaneous squamous cell carcinoma, a significantly greater level of deregulation of selected miRNAs was observed in perilesional skin fluid compared to that in blood levels.

A família, especialmente os pais e irmãos, constitui o núcleo onde se formam as primeiras relações interpessoais, proporcionando apoio e segurança. Quando um irmão é diagnosticado com Perturbação do Espectro do Autismo (PEA), ocorrem alterações significadas nas dinâmicas familiares para um ajuste às necessidades específicas da criança com PEA. Essas mudanças, que afetam rotinas e o tempo de qualidade em família, podem influenciar o comportamento, as competências socioemocionais e as relações entre irmãos. Propõe-se analisar, através de uma revisão integrativa da literatura, a influência da PEA nas relações entre irmãos. Deste modo, foram identificados 18 estudos publicados entre 2015 e 2024, cujas abordagens metodológicas se centram em pesquisas qualitativas, quantitativas e mistas. As bases de dados utilizadas foram: Web of Science, Scopus e Scielo. A pesquisa foi conduzida com recurso a palavras-chave em português europeu e do brasil e inglês, nomeadamente, português: PEA OU autismo E irmãos E relações; irmãos E PEA; inglês: ASD OR autism spectrum disorder AND siblings; siblings AND ASD. O estudo conclui que, embora as relações entre irmãos com e sem PEA sejam desafiadoras, elas também promovem o desenvolvimento de competências sociais e emocionais. Ressalta-se a importância do suporte familiar e comunitário para minimizar os impactos negativos e fortalecer os vínculos familiares.

Future large-scale combat operations could involve delayed patient evacuation because of contested theaters of operations where United States and allied forces are unlikely to have air superiority. Prolonged casualty care could be more prevalent with delays in evacuation, requiring personnel prepared to provide critical care for injured warfighters and innovation aimed at supporting patients for longer periods of time. We conduct a review on the incidence and mortality rates of organ failure, describe the potential benefits of organ support, and offer recommendations to improve the care of patients in future conflicts. We performed a review examining the incidence and mortality of organ failure and the documented use of advanced modalities in the care of patients with organ failure. The search was conducted from the database's inception to June 21, 2024. Primary literature from previous review articles was also incorporated into this review. Authors reviewed relevant abstracts and full manuscripts. Acute respiratory failure and the need for respiratory support are common in severely injured trauma patients. Acute renal failure and the need for advanced renal support were also found to be common after injury. Although less common, advanced extracorporeal support, when required, can improve patient outcomes. In order to prepare for future conflicts, investment in personnel training, sustainment, and innovative technology will be essential to saving lives.

BackgroundIn relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here defined as a switch to a lower efficacy therapy, is often considered by patients and physicians, but evidence to guide such decisions is scarce. In this study, we aimed to compare clinical outcomes between patients who de-escalated therapy versus those who continued their therapy.MethodsIn this retrospective analysis of data from an observational, longitudinal cohort of 87,239 patients with multiple sclerosis (MS) from 186 centers across 43 countries, we matched treatment episodes of adult patients with RRMS who underwent treatment de-escalation from either high- to medium-, high- to low-, or medium- to low-efficacy therapy with counterparts that continued their treatment, using propensity score matching and incorporating 11 variables. Relapses and 6-month confirmed disability worsening were assessed using proportional and cumulative hazard models.ResultsMatching resulted in 876 pairs (de-escalators: 73% females, median [interquartile range], age 40.2 years [33.6, 48.8], Expanded Disability Status Scale [EDSS] 2.5 [1.5, 4.0]; non-de-escalators: 73% females, age 40.8 years [35.5, 47.9], and EDSS 2.5 [1.5, 4.0]), with a median follow-up of 4.8 years (IQR 3.0, 6.8). Patients who underwent de-escalation faced an increased hazard of future relapses (hazard ratio 2.36 and 95% confidence intervals [CI] [1.79–3.11], p < 0.001), which was confirmed when considering recurrent relapses (2.43 [1.97–3.00], p < 0.001). It was also consistent across subgroups stratified by age, sex, disability, disease duration, and time since last relapse.ConclusionsOn the basis of this observational analysis, de-escalation may not be recommended as a universal treatment strategy in RRMS. The decision to de-escalate should be considered on an individual basis, as its safety is not clearly guided by specific patient or disease characteristics evaluated in this study.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40263-025-01164-w.

Abstract The logging industry in the United States faces a demographic shift with aging owners and a decline in intergenerational business transfers. This pilot study explores the potential for new businesses led by minority groups, beginning loggers, and young entrepreneurs in the southeastern United States. Interviews with nine minority, beginning, and young (MBY) logging business owners and four forestry/logging associations uncovered challenges, including high startup costs, limited access to financing and funds, difficulty hiring skilled workers, low profit margins, and a lack of established professional networks. These MBY loggers are well educated and exhibit productive businesses, with an average investment of between $100,000 and $499,999. Proposed solutions to help more MBY logging business owners get started encompass government grants, low-interest loans, marketing initiatives, and legislative measures. Results are limited, and this study serves as a first glimpse into MBY logging business owners’ challenges; additional attention is needed for this population of logging business owners. Study Implications: Understanding the present status and challenges faced by minority, beginning, and young (MBY) logging business owners is instrumental for the industry, as the trend of intergenerational logging business transfer is declining. The study’s results suggest that support from the forest products industry and the government, such as government grants, low-interest loans, and strategic marketing, can enhance the sustainability of MBY logging businesses. These measures, coupled with legislative support, could help to address immediate challenges, such as high startup costs, and lay the groundwork for fostering a resilient logging industry.

Dry electrode manufacturing processes are appealing as they can potentially mitigate the economic and environmental consequences of traditional slurry techniques. Understanding the interactions among active material (AM), conductive agent, and binder in dry-made electrodes is crucial for achieving the desired electrode performance and durability. In this study, we conducted a comprehensive investigation of the effects of the different electrode formulations by altering the ratio of polyvinylidene fluoride (PVDF) binder and carbon black (CB) for LiNi0.8Mn0.1Co0.1O2 (NMC811) electrodes made using a dry coating process. Specifically, we examined four distinct electrode formulations: 96:3:1, 96:2:2, 90:7.5:2.5, and 90:5:5 (AM: PVDF: CB), equivalent to PVDF/CB mass ratios of 1:1 and 3:1. We found that a high PVDF content at PVDF/CB ratio of 3:1 provides high mechanical strength. However, the electrode ionic conductivity decreases due to the insulating aggregates of PVDF. The PVDF/CB ratio of 1:1 approaches the optimum ratio for balanced electronic and ionic conductivities and electrode mechanical strength, hence leading to enhanced electrochemical performance. For electrodes with the PVDF/CB ratio of 1:1, we observed surprisingly that electrode with higher AM content (e.g., 96%) showed a comparable C-rate and full-cell cycling performance to that with lower AM content (90%).

Introduction: One strategy to mitigate progressive multifocal leukoencephalopathy (PML) risk is to switch to other highly effective disease-modifying therapies (DMTs). However, the optimal switch DMT following natalizumab (NTZ) discontinuation is yet to be determined. Objective: The objective of the study is to determine the most effective and tolerable DMTs to switch to following NTZ discontinuation due to John Cunningham virus (JCV) antibody positivity. Methods: This is a multicenter observational cohort study that included all stable relapsing-remitting multiple sclerosis (MS) patients who were treated with NTZ for at least 6 months before switching therapy due to JCV antibody positivity. Results: Of 321 patients, 255 switched from NTZ to rituximab/ocrelizumab, 52 to fingolimod, and 14 to alemtuzumab, with higher annualized relapse rate (ARR) in fingolimod switchers (0.193) compared with rituximab/ocrelizumab or alemtuzumab (0.028 and 0.032, respectively). Fingolimod switchers also had increased disability progression (p = 0.014) and a higher proportion developed magnetic resonance imaging (MRI) lesions compared with rituximab/ocrelizumab (62.9% vs. 13.0%, p < 0.001, and 66.6% vs. 24.0%, p < 0.001, respectively). Mean drug survival favored rituximab/ocrelizumab or alemtuzumab over fingolimod (p < 0.001). Conclusion: Our study shows superior effectiveness of rituximab/ocrelizumab and alemtuzumab compared with fingolimod in stable patients switching from NTZ due to JC virus antibody positivity.

Introduction: Right Heart Catheterization (RHC) is the gold standard diagnostic test to confirm Pulmonary Arterial Hypertension (PAH). However, not all patients receive a RHC to confirm diagnosis. Hypothesis: This study analyzed a real-world PAH dataset to understand factors predictive of RHC being used to confirm diagnosis. Methods: Data were analyzed from the 2022 Adelphi PAH Disease Specific Programme™ containing physician-provided patient information for PAH patients in the US, France, Germany, Italy, Spain, UK and Japan. As our outcome (RHC at diagnosis) is binary, logistic regression was used behind LASSO for 113 covariates (predictors). LASSO regression inputs many covariates, only those associated with the outcome are presented. Each covariate is tested individually and against all others. In LASSO an odds ratio (OR) is generated. An OR &gt; 1 or more indicates a predictor is associated with a higher likelihood of RHC at diagnosis, an OR &lt; 1 indicates a lower likelihood. RHC at diagnosis was physician-confirmed from patient records. Results: A total of 529 PAH patients with complete data for all covariates were analyzed. Mean age was 55 and 51% were female. Overall, 75% received a RHC at diagnosis. Patient refusal (34%) and deemed unnecessary by managing physician due to other testing (29%) were the most frequently cited reasons for lack of RHC. Of the 113 initial predictors, 24 were considered important in predicting RHC ( Figure 1 ). The leading predictors for RHC at diagnosis were patients classified as functional class (FC) III, those experiencing symptoms of dyspnea, palpitations and cyanosis, and those diagnosed at an accredited expert pulmonary hypertension (PH) center. Conclusions: Results indicate that RHC is more likely to be used for patients presenting with a higher FC, key PAH symptoms and diagnosed at PH expert centers. Further emphasis should be placed on RHC at diagnosis particularly within non-specialist settings to help achieve accurate diagnosis.

Skilled nursing facility (SNF) care is frequently used after cardiac surgery, but the patterns and determinants of use have not been well understood. The objective of this study was to evaluate determinants and outcomes associated with SNF use after isolated coronary artery bypass grafting. A retrospective analysis of Medicare Fee-For-Service claims linked to the Society of Thoracic Surgeons clinical data was conducted on isolated coronary artery bypass grafting patients without prior SNF use in Michigan between 2011 and 2019. Descriptive analysis evaluated the frequency, trends, and variation in SNF use across 33 Michigan hospitals. Multivariable mixed-effects regression was used to evaluate patient-level demographic and clinical determinants of SNF use and its effect on short- and long-term outcomes. In our sample of 8614 patients, the average age was 73.3 years, 70.5% were male, and 7.7% were listed as non-White race. An SNF was utilized by 1920 (22.3%) patients within 90 days of discharge and varied from 3.2% to 58.3% across the 33 hospitals. Patients using SNFs were more likely to be female, older, non-White, with more comorbidities, worse cardiovascular function, a perioperative morbidity, and longer hospital lengths of stay. Outcomes were significantly worse for SNF users, including more frequent 90-day readmissions and emergency department visits and less use of home health and rehabilitation services. SNF users had higher risk-adjusted hazard of mortality (hazard ratio, 1.41 [95% CI, 1.26-1.57]; P<0.001) compared with non-SNF users and had 2.7-percentage point higher 5-year mortality rate in a propensity-matched cohort of patients (18.1% versus 15.4%; P<0.001). The use of SNF care after isolated coronary artery bypass grafting was frequent and variable across Michigan hospitals and associated with worse risk-adjusted outcomes. Standardization of criteria for SNF use may reduce variability among hospitals and ensure appropriateness of use.